IP Library Granted Patent US 11,491,204
Granted Patent B2
US 11,491,204 · App. 16/935,534 · Granted Nov 8, 2022

Composition comprising poly I:C and LAG-3-IGG fusion protein

Inventors: Tomoya Miyakawa (Tokyo, JP); Shun Doi (Tokyo, JP); Koji Tamada (Yamaguchi, JP)
Assignee: Cytlimic Inc.
A61K38/177A61K38/00A61K38/1709A61K38/18A61K39/00A61K39/0011A61K39/39A61K45/00A61K45/05A61P35/00A61P37/02C07K14/475C07K19/00C12N15/117A61K2039/555A61K2039/55511A61K2039/57A61K2039/585C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,491,204
App. No.
16/935,534
Granted
Nov 8, 2022
Kind
B2
Abstract

The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Claims (14)

1. A pharmaceutical composition comprising

Poly I:C or a salt thereof and

a fusion protein of lymphocyte activation gene 3 (LAG-3) protein and IgG.

2. The pharmaceutical composition according to claim 1 , consisting of

a preparation comprising Poly I:C or a salt thereof and

a preparation comprising a fusion protein of LAG-3 protein and IgG,

wherein the two preparations are formulated for combined administration.

3. The pharmaceutical composition according to claim 1 , further comprising at least one cancer-antigen derived peptide.

4. The pharmaceutical composition according to claim 3 , consisting of

a preparation comprising Poly I:C or a salt thereof,

a preparation comprising a fusion protein of LAG-3 protein and IgG, and

a preparation comprising at least one type of cancer-antigen derived peptide

wherein the three preparations are formulated for combined administration.

5. The pharmaceutical composition according to claim 3 , comprising two or more cancer-antigen derived peptides.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2023
From: CYTLIMIC INC.
To: NEC CORPORATION
Reel/Frame 062357/0203 →
Priority Claims (3)
JP 2015-078684 · Apr 7, 2015 · national
JP 2015-198066 · Oct 5, 2015 · national
JP 2016-032046 · Feb 23, 2016 · national
Continuity (2)
Division 15564604
Related Publication 20210000916A1 · Jan 7, 2021